{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:13:59Z","timestamp":1788236039251,"version":"build-2803163510"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal gammopathy of renal significance (MGRS) has introduced a new perspective to several well-known disease entities impacting nephrology, haematology and pathology. Given the constantly changing disease spectrum of these entities, it is clinically imperative to establish diagnostic and treatment pathways supported by evidence-based medicine. MGRS is a disease of the kidney, secondary to plasma cell clonal proliferation or immune dysfunction, requiring therapeutic intervention to eradicate the offending clone. To fully understand the disease(s), it is prerequisite to determine the significance of the findings. The diagnostic work up should be extensive due to the wide heterogeneity of clinical presentation, ultimately necessitating kidney biopsy. Particular patient profiles such as AL amyloidosis, which may be diagnosed through biopsies of other tissues\/organs, may be an exception. Treatment decisions should be formulated by multi-disciplinary consensus: nephrologists, haematologists and pathologists. The ultimate goal in managing MGRS is eradication of the offending plasma cell clone which requires targeted chemotherapy and, in eligible cases, haematopoietic stem cell transplantation. We present a review of diagnostic procedures, treatment options and advances in the last few years in the management of MGRS in an effort to acquaint specialists with this new face of several older diseases.<\/jats:p>","DOI":"10.1093\/ndt\/gfy259","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T16:18:01Z","timestamp":1531757881000},"page":"1440-1452","source":"Crossref","is-referenced-by-count":13,"title":["The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance"],"prefix":"10.1093","volume":"34","author":[{"given":"Krzysztof","family":"Batko","sequence":"first","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"first","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warszawa, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"first","affiliation":[{"name":"Departament of Hematology, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Vesole","sequence":"first","affiliation":[{"name":"Myeloma DIvision, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A","family":"Gertz","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"first","affiliation":[{"name":"Service d`Hematologie CHU, Hopital de la Miletrie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Suska","sequence":"first","affiliation":[{"name":"Departament of Hematology, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Krzanowski","sequence":"first","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142aw","family":"Su\u0142owicz","sequence":"first","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek S","family":"Malyszko","sequence":"first","affiliation":[{"name":"1st Department of Nephrology, Medical University, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Krzanowska","sequence":"first","affiliation":[{"name":"Departament of Nephrology, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"2020070205540147900_gfy259-B1","first-page":"814","article-title":"Monoclonal gammopathy of undetermined significance","volume":"64","author":"Kyle","year":"1978","journal-title":"Natural History in 241 Cases. Am J Med [Internet]"},{"key":"2020070205540147900_gfy259-B2","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med [Internet]"},{"key":"2020070205540147900_gfy259-B4","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10\u201349 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"2020070205540147900_gfy259-B5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12\u2009482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia [Internet]"},{"key":"2020070205540147900_gfy259-B6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.canep.2014.04.006","article-title":"Epidemiology of monoclonal gammopathy of undetermined significance (MGUS): the experience from the specialized registry of hematologic malignancies of Basse-Normandie (France)","volume":"38","author":"Cabrera","year":"2014","journal-title":"Cancer Epidemiol [Internet]"},{"key":"2020070205540147900_gfy259-B7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","article-title":"Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition","volume":"87","author":"Therneau","year":"2012","journal-title":"Mayo Clin Proc [Internet]"},{"key":"2020070205540147900_gfy259-B8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"2020070205540147900_gfy259-B9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet [Internet]"},{"key":"2020070205540147900_gfy259-B10","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.18632\/oncotarget.23412","article-title":"Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients","volume":"9","author":"Steiner","year":"2018","journal-title":"Oncotarget [Internet]"},{"key":"2020070205540147900_gfy259-B11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis [Internet]"},{"key":"2020070205540147900_gfy259-B13","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol [Internet]"},{"key":"2020070205540147900_gfy259-B14","first-page":"2018","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran","year":"2016","journal-title":"Nat Publishing Group [Internet]"},{"key":"2020070205540147900_gfy259-B15","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol [Internet]"},{"key":"2020070205540147900_gfy259-B19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5527\/wjn.v6.i2.72","article-title":"Monoclonal gammopathy of renal significance: diagnostic workup","volume":"6","author":"Correia","year":"2017","journal-title":"WJN"},{"key":"2020070205540147900_gfy259-B20","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","article-title":"Renal monoclonal immunoglobulin deposition disease: the disease spectrum","volume":"12","author":"Lin","year":"2001","journal-title":"J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2215\/CJN.06760909","article-title":"Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy","volume":"5","author":"Sethi","year":"2010","journal-title":"Clin J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc [Internet]"},{"key":"2020070205540147900_gfy259-B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ckj\/sfv002","article-title":"Light and heavy chain deposition disease associated with CH1 deletion","volume":"8","author":"Cohen","year":"2015","journal-title":"Clin Kidney J [Internet]"},{"key":"2020070205540147900_gfy259-B24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2012","journal-title":"Clin J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B25","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/ndt\/gfu045","article-title":"Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist","volume":"29","author":"Sicard","year":"2014","journal-title":"Nephrol Dial Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1681\/ASN.V8170","article-title":"A reevaluation of routine electron microscopy in the examination of native renal biopsies","volume":"8","author":"Haas","year":"1997","journal-title":"J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ki.2015.195","article-title":"Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits","volume":"88","author":"Larsen","year":"2015","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol Dial Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12882-018-0927-0","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report","volume":"19","author":"Alonso-Titos","year":"2018","journal-title":"BMC Nephrol"},{"key":"2020070205540147900_gfy259-B31","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24756","article-title":"Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease","volume":"92","author":"Mohan","year":"2017","journal-title":"Am J Hematol"},{"key":"2020070205540147900_gfy259-B33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2016.10.026","article-title":"The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits","volume":"91","author":"Vignon","year":"2017","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ekir.2017.07.008","article-title":"Membranous glomerulopathy with light chain-restricted deposits: a clinicopathological analysis of 28 cases","volume":"2","author":"Best Rocha","year":"2017","journal-title":"Kidney Int Rep [Internet]"},{"key":"2020070205540147900_gfy259-B35","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","article-title":"Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies","volume":"59","author":"Nasr","year":"2012","journal-title":"Am J Kidney Dis [Internet]"},{"key":"2020070205540147900_gfy259-B36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.blre.2015.12.001","article-title":"Monoclonal gammopathy: the good, the bad and the ugly","volume":"30","author":"Glavey","year":"2016","journal-title":"Blood Rev [Internet]"},{"key":"2020070205540147900_gfy259-B37","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem [Internet]"},{"key":"2020070205540147900_gfy259-B38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2014.333","article-title":"The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease","volume":"87","author":"Yadav","year":"2015","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B39","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1038\/bcj.2014.56","article-title":"Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment","volume":"4","author":"Sugihara","year":"2014","journal-title":"Blood Cancer J [Internet]"},{"key":"2020070205540147900_gfy259-B40","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B41","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-017-1594-y","article-title":"Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity","author":"Ciocchini","year":"2017","journal-title":"Int Urol Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2017121319","article-title":"The complexity and heterogeneity of monoclonal immunoglobulin\u2013associated renal diseases","volume":"29","author":"Sethi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2020070205540147900_gfy259-B43","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B44","first-page":"502","article-title":"Abnormal serum free light chain ratio does not always indicate monoclonal gammopathy","volume":"125","author":"Jurczyszyn","year":"2015","journal-title":"Polskie Archiwum Medycyny Wewnetrznej [Internet]"},{"key":"2020070205540147900_gfy259-B45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.14740\/jocmr2802w","article-title":"Serum free light chain assay and \u03ba\/\u03bb ratio: performance in patients with monoclonal gammopathy-high false negative rate for \u03ba\/\u03bb ratio","volume":"9","author":"Singh","year":"2017","journal-title":"J Clin Med Res"},{"key":"2020070205540147900_gfy259-B46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1258\/acb.2009.009038","article-title":"Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy","volume":"46","author":"Fulton","year":"2009","journal-title":"Ann Clin Biochem [Internet]"},{"key":"2020070205540147900_gfy259-B47","first-page":"1801","article-title":"Urine immunofixation electrophoresis remains important and is complementary to serum free light chain","volume":"49","author":"Levinson","year":"2011","journal-title":"Clin Chem Lab Med [Internet]"},{"key":"2020070205540147900_gfy259-B48","doi-asserted-by":"crossref","first-page":"562","DOI":"10.14740\/jocmr3383w","article-title":"Serum free light chains in neoplastic monoclonal gammopathies: relative under-detection of lambda dominant Kappa\/Lambda ratio, and underproduction of free lambda light chains, as compared to kappa light chains, in patients with neoplastic monoclonal gammopathies","volume":"10","author":"Lee","year":"2018","journal-title":"J Clin Med Res"},{"key":"2020070205540147900_gfy259-B49","doi-asserted-by":"crossref","first-page":"82268","DOI":"10.18632\/oncotarget.19391","article-title":"Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget [Internet]"},{"key":"2020070205540147900_gfy259-B50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2016.06.028","article-title":"Diagnostic performances of M-protein tests according to the clinical presentations of kidney disease","volume":"33","author":"Koo","year":"2016","journal-title":"Eur J Intern Med [Internet]"},{"key":"2020070205540147900_gfy259-B51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B52","first-page":"929","article-title":"Laboratory testing in monoclonal gammopathy of renal significance (MGRS)","volume":"54","author":"Leung","year":"2016","journal-title":"Clin Chem Lab Med [Internet]"},{"key":"2020070205540147900_gfy259-B53","doi-asserted-by":"crossref","first-page":"e38061","DOI":"10.1371\/journal.pone.0038061","article-title":"Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (AL)","volume":"7","author":"Ramirez-Alvarado","year":"2012","journal-title":"PLoS ONE [Internet]"},{"key":"2020070205540147900_gfy259-B54","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2215\/CJN.03160316","article-title":"Bridging the divide: an onco-nephrologic approach to the monoclonal gammopathies of renal significance","volume":"11","author":"Hogan","year":"2016","journal-title":"Clin J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk [Internet]"},{"key":"2020070205540147900_gfy259-B56","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"key":"2020070205540147900_gfy259-B57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2015.133629","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Dimopoulos","year":"2016","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B58","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00432-012-1212-4","article-title":"Successful treatment of patients with newly diagnosed\/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone","volume":"138","author":"P\u00f6nisch","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"2020070205540147900_gfy259-B59","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ajh.23798","article-title":"Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas","volume":"89","author":"Perry","year":"2014","journal-title":"Am J Hematol"},{"key":"2020070205540147900_gfy259-B60","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: results from a Phase II trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020070205540147900_gfy259-B61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron [Internet]"},{"key":"2020070205540147900_gfy259-B62","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the Phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"JCO"},{"key":"2020070205540147900_gfy259-B63","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1182\/blood-2011-05-353995","article-title":"Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment","volume":"118","author":"Morabito","year":"2011","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B64","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"2020070205540147900_gfy259-B65","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3109\/10428194.2013.836600","article-title":"The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis","volume":"55","author":"Nordstrom","year":"2014","journal-title":"Leuk Lymphoma [Internet]"},{"key":"2020070205540147900_gfy259-B66","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","article-title":"Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents","volume":"34","author":"Roussou","year":"2010","journal-title":"Leuk Res [Internet]"},{"key":"2020070205540147900_gfy259-B67","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","article-title":"Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency","volume":"16","author":"Tosi","year":"2010","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B68","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer [Internet]"},{"key":"2020070205540147900_gfy259-B69","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1080\/10428194.2016.1177181","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials","volume":"57","author":"Siegel","year":"2016","journal-title":"Leuk Lymphoma [Internet]"},{"key":"2020070205540147900_gfy259-B70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol [Internet]"},{"key":"2020070205540147900_gfy259-B71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2011.87","article-title":"High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease","volume":"47","author":"Telio","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2020070205540147900_gfy259-B72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbmt.2017.08.031","article-title":"High-dose melphalan and stem cell transplantation in patients on dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease","volume":"24","author":"Batalini","year":"2018","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B73","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"key":"2020070205540147900_gfy259-B74","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","article-title":"Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors","volume":"42","author":"Pozzi","year":"2003","journal-title":"Am J Kidney Dis [Internet]"},{"key":"2020070205540147900_gfy259-B75","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-011-1401-2","article-title":"Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment","volume":"91","author":"Song","year":"2012","journal-title":"Ann Hematol [Internet]"},{"key":"2020070205540147900_gfy259-B76","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CPAA.S144606","article-title":"Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function","volume":"9","author":"Li","year":"2017","journal-title":"CPAA"},{"key":"2020070205540147900_gfy259-B78","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1038\/bcj.2017.47","article-title":"Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib","volume":"7","author":"Kastritis","year":"2017","journal-title":"Blood Cancer J"},{"key":"2020070205540147900_gfy259-B79","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia [Internet]"},{"key":"2020070205540147900_gfy259-B80","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B81","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2215\/CJN.12811216","article-title":"Endothelium-dependent and -independent vascular function in advanced chronic kidney disease","volume":"12","author":"Kopel","year":"2017","journal-title":"CJASN"},{"key":"2020070205540147900_gfy259-B82","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A Phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B83","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B84","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B85","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/10428194.2012.671481","article-title":"Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature","volume":"54","author":"Payet","year":"2013","journal-title":"Leuk Lymphoma [Internet]"},{"key":"2020070205540147900_gfy259-B86","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B87","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B88","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"2020070205540147900_gfy259-B89","first-page":"e573","article-title":"Bortezomib in multiple myeloma: systematic review and clinical considerations","volume":"21","author":"Kouroukis","year":"2014","journal-title":"Curr Oncol (Toronto, Ont.) [Internet]"},{"key":"2020070205540147900_gfy259-B90","doi-asserted-by":"crossref","first-page":"e5202","DOI":"10.1097\/MD.0000000000005202","article-title":"Bortezomib-based treatment for multiple myeloma patients with renal impairment: a systematic review and meta-analysis of observational studies","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine [Internet]"},{"key":"2020070205540147900_gfy259-B91","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"JCO"},{"key":"2020070205540147900_gfy259-B92","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy\u2013associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B93","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B94","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1080\/10428194.2016.1267349","article-title":"Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens","volume":"58","author":"Ziogas","year":"2017","journal-title":"Leuk Lymphoma [Internet]"},{"key":"2020070205540147900_gfy259-B95","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ekir.2017.11.017","article-title":"Novel therapies in light chain amyloidosis","volume":"3","author":"Milani","year":"2018","journal-title":"Kidney Int Rep [Internet]"},{"key":"2020070205540147900_gfy259-B96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2010.08184.x","article-title":"Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia","volume":"150","author":"Spizzo","year":"2010","journal-title":"Br J Haematol [Internet]"},{"key":"2020070205540147900_gfy259-B97","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ajh.21258","article-title":"Response to bortezomib in refractory Type I cryoglobulinemia","volume":"83","author":"Talamo","year":"2008","journal-title":"Am J Hematol"},{"key":"2020070205540147900_gfy259-B98","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"2020070205540147900_gfy259-B99","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ncpneph0133","article-title":"Drug insight: rituximab in renal disease and transplantation","volume":"2","author":"Salama","year":"2006","journal-title":"Nat Clin Pract Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.10213","article-title":"Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis","volume":"71","author":"Jillella","year":"2002","journal-title":"Am J Hematol"},{"key":"2020070205540147900_gfy259-B102","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.10611110","article-title":"Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab","volume":"6","author":"Guiard","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205540147900_gfy259-B103","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ajh.24984","article-title":"Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance","volume":"93","author":"Ribes","year":"2018","journal-title":"Am J Hematol"},{"key":"2020070205540147900_gfy259-B104","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","article-title":"Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites","volume":"75","author":"Darwish","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020070205540147900_gfy259-B105","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00432-013-1513-2","article-title":"Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure","volume":"139","author":"P\u00f6nisch","year":"2013","journal-title":"J Cancer Res Clin Oncol [Internet]"},{"key":"2020070205540147900_gfy259-B106","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"2020070205540147900_gfy259-B107","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.3324\/haematol.2018.191122","article-title":"Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma","volume":"103","author":"Rocchi","year":"2018","journal-title":"Haematologica [Internet]"},{"key":"2020070205540147900_gfy259-B108","article-title":"Daratumumab for severe refractory proliferative glomerulonephritis with monoclonal immune deposits (PGNMID)","author":"Anand","year":"2017","journal-title":"ATC Abstr [Internet]"},{"key":"2020070205540147900_gfy259-B109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis [Internet]"},{"key":"2020070205540147900_gfy259-B110","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2010.1","article-title":"Recurrent membranoproliferative glomerulonephritis after kidney transplantation","volume":"77","author":"Lorenz","year":"2010","journal-title":"Kidney Int [Internet]"},{"key":"2020070205540147900_gfy259-B111","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2215\/CJN.10641015","article-title":"A patient with abnormal kidney function and a monoclonal light chain in the urine","volume":"11","author":"Leung","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205540147900_gfy259-B112","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood [Internet]"},{"key":"2020070205540147900_gfy259-B113","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma [Internet]"},{"key":"2020070205540147900_gfy259-B114","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205540147900_gfy259-B115","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"2020070205540147900_gfy259-B116","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1399-0012.2011.01539.x","article-title":"Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy","volume":"26","author":"Soltero","year":"2012","journal-title":"Clin Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B117","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/TP.0b013e318225db2c","article-title":"Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants","volume":"92","author":"Jimenez-Zepeda","year":"2011","journal-title":"Transplantation [Internet]"},{"key":"2020070205540147900_gfy259-B118","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000337482","article-title":"Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation","volume":"35","author":"Naina","year":"2012","journal-title":"Am J Nephrol"},{"key":"2020070205540147900_gfy259-B119","doi-asserted-by":"crossref","first-page":"c228","DOI":"10.1159\/000341760","article-title":"Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias","volume":"120","author":"Bansal","year":"2012","journal-title":"Nephron Clin Pract [Internet]"},{"key":"2020070205540147900_gfy259-B120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bmt.2008.179","article-title":"High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease","volume":"42","author":"Hassoun","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2020070205540147900_gfy259-B121","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B122","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease","volume":"23","author":"Lorenz","year":"2008","journal-title":"Nephrol Dial Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B123","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ckj\/sfx001","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab","volume":"10","author":"Merhi","year":"2017","journal-title":"Clin Kidney J [Internet]"},{"key":"2020070205540147900_gfy259-B124","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/ndt\/gfr251","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases","volume":"26","author":"Barbour","year":"2011","journal-title":"Nephrol Dial Transplant [Internet]"},{"key":"2020070205540147900_gfy259-B125","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol [Internet]"},{"key":"2020070205540147900_gfy259-B126","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1097\/TP.0000000000001884","article-title":"Monoclonal gammopathy of undetermined significance after kidney transplantation","volume":"101","author":"Alfano","year":"2017","journal-title":"Transplantation [Internet]"},{"key":"2020070205540147900_gfy259-B127","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.transproceed.2015.08.023","article-title":"Outcomes of monoclonal gammopathy of undetermined significance in patients who underwent kidney transplantation","volume":"47","author":"Bancu","year":"2015","journal-title":"Transplant Proc [Internet]"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/9\/1440\/33456006\/gfy259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/9\/1440\/33456006\/gfy259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:43:28Z","timestamp":1720428208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/9\/1440\/5086133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,28]]},"references-count":127,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,8,28]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy259","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2018,8,28]]}}}